obiadminpharma
OBI has signed a non-binding MOU to form a strategic partnership to develop novel bispecific antibody cancer treatments
Date of occurrence of the event:26 May 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No applicable …
OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424
Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types TAIPEI, Taiwan, May 20, 2020 — OBI Pharma, Inc. (TPEx: 4174), a …
Supplementary statement for 2020 Shareholders’ Meeting (Change in location and new items)
Date of the board of directors resolution:May 08, 2020 Date for convening the shareholders’ meeting:Jun 22, 2020 Location for convening the shareholders’ meeting:Courtyard Taipei, 7F Supernova Ballroom (7F, No.359, Sec. …
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to proceed Phase III human clinical study
Date of occurrence of the event: Apr 10, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No …
OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic
TAIPEI, TAIWAN. APRIL 8, 2020– OBI Pharma has been closely monitoring the impact of the COVID-19 pandemic worldwide. We realize the intense challenges that patients and our clinical research investigators …
Due to the tense situation of Novel Coronavirus Disease (COVID-19), company decided to pause the recruitment of Global Phase III clinical study for 3 months and will restart recruitment when epidemic gets controlled.
Date of occurrence of the event: Apr 06, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No …
Updates on company’s negotiable securities for investors’ information
1.Date of occurrence of the event: Mar 23, 2020 2.Cause of occurrence: Notified by Taipei Exchange (TPEx) to release information 3.Financial and business information: (1 ) Latest 1 month SUBJECT …
Announcement on change of accountant due to internal adjustment of accounting firm
Date of occurrence of the event: Mar 13, 2020 Name of the original accounting firm and name of the original CPA: PwC Taiwan, Yu-Kuan Lin; PwC Taiwan, Sheng-Wei Deng Name …
The Board of Directors resolved to hold 2020 Annual General Meeting
Date of the board of directors resolution: Mar 13, 2020 Date for convening the shareholders’ meeting: Jun 22, 2020 Location for convening the shareholders’ meeting: Masterlink Securities Education and Training …
The board of directors have resolved not to distribute dividends for 2019
Date of the board of directors resolution: Mar 13, 2020 Year or quarter which dividends belong to : 2019 Period which dividends belong to: Jan 01, 2019 to Dec 31, …